Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, October 30, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Express Scripts Holding Company (NASDAQ: ESRX), Baxter International Inc. (NYSE: BAX), IDEXX Laboratories, Inc. (NASDAQ: IDXX), KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH), and The Spectranetics Corporation (NASDAQ: SPNC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Express Scripts Holding Company Research Report
On October 24, 2013, Express Scripts Holding Company (Express Scripts) released its Q3 2013 results. Express Scripts registered revenues of $25.9 billion in Q3 2013, compared to revenues of $26.8 billion in Q3 2012. Express Scripts posted net income attributable to the Company of $426.7 million or $0.52 per diluted share, compared to $391.4 million or $0.47 per diluted share in Q3 2012. George Paz, Chairman and CEO of Express Scripts, stated, "As the healthcare landscape continues to evolve, we are well-positioned to help clients and members successfully navigate a rapidly-changing environment full of new rules and regulations. Our breadth of client solutions across traditional pharmacy benefit management, specialty management, and Medicare Part D is unparalleled in the industry." The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/91a7_ESRX]
Baxter International Inc. Research Report
On October 23, 2013, Baxter International Inc. (Baxter) launched HEMOPATCH Sealing Hemostat, a novel collagen-based hemostatic device, following CE mark approval in Europe. Russell Holscher, Vice President of Research and Development in Baxter's BioSurgery business, commented, "HEMOPATCH is a significant innovation in the field of surgical hemostasis and is a valuable enhancement to the portfolio of biosurgical products offered by Baxter." Holscher added, "Importantly, the robust development process, including evaluation of more than 400 prototypes with feedback from more than 200 surgeons, exemplifies the company's commitment to customer-centric innovation. This hemostat will offer surgeons a valuable new tool. We plan to support the registration and launch of HEMOPATCH in additional countries in the coming years." The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/163d_BAX]
IDEXX Laboratories, Inc. Research Report
On October 22, 2013, IDEXX Laboratories, Inc. (IDEXX) released its Q3 2013 results. IDEXX registered revenues of $338.3 million during the quarter, an increase of 7.2% YoY. For Q3 2013, the Company posted net income attributable to shareholders of $45.7 million, up 6.6% YoY IDEXX reported diluted EPS of $0.86 for Q3 2013, compared to $0.76 in Q3 2012. Commenting on the results, Jonathan Ayers, Chairman and CEO of IDEXX, said, "For the quarter, I am pleased with the Company's 7.4% organic revenue growth, driven by the Companion Animal Group's 8.7% organic growth. This performance represents a significant improvement from first half organic growth of 4.4% for the total Company and 5.3% for the Companion Animal Group, respectively." The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/bf62_IDXX]
KYTHERA Biopharmaceuticals, Inc. Research Report
On October 7, 2013, KYTHERA Biopharmaceuticals, Inc. (KYTHERA) announced additional patient satisfaction and efficacy data from REFINE-1 and REFINE-2, two pivotal Phase III clinical trials of ATX-101 for the reduction of submental fat, which is commonly present as a double chin. According to Kythera, new data demonstrates that the majority of ATX-101 subjects reported satisfaction with their treatment as well as improvements on visual and psychological impacts of their "chin fat." Further, the Company reported that the vast majority of subjects had a reduction in submental fat as assessed independently by clinicians and patients, and most adverse events were transient, local to the treatment area, and mild to moderate in severity. Frederick Beddingfield, III, M.D., Ph.D., Chief Medical Officer, KYTHERA, said, "These new findings, along with the previously released data, reinforce that ATX-101 effectively reduces fat under the chin, improving the appearance of the submental profile. Importantly, this results in high patient satisfaction, which is critical in the field of aesthetic medicine." The Full Research Report on KYTHERA Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b90a_KYTH]
The Spectranetics Corporation Research Report
On October 24, 2013, The Spectranetics Corporation (Spectranetics) released its Q3 2013 results. For Q3 2013, Spectranetics registered revenues of $39.8 million, up 12.9% YoY. The Company posted net income of $434,000 or $0.01 per diluted share, compared to $905,000 or $0.03 per diluted share in Q3 2012. Scott Drake, President and CEO of Spectranetics, stated, "The third quarter of 2013 reflects strong commercial and operational execution. We extended our track record of double digit revenue growth and significantly improved our gross margin." Drake continued, "We have enrolled 216 patients in EXCITE ISR, bringing us closer to our goal of achieving the in-stent restenosis indication and proving clinical superiority. We remain on track with our plans to accelerate revenue growth as we execute several compelling growth drivers, including lead management market development, meaningful new product launches, pursuit of the ISR indication and expansion of our sales footprint." The Full Research Report on The Spectranetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/82e6_SPNC]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.